Artificial Intelligence

With a new regulatory chief, Ray Therapeutics accelerates its mission to bring its goggle-free optogenetic therapies for blindness through clinical trials.

An Indiana firm's implantable pump gains key FDA status, promising a future with less mental burden for Type 1 Diabetes patients. But the road is long.

Ceva's AI licensing revenue soared in 2025, securing deals with a top PC OEM and Microchip, signaling a major industry shift to on-device intelligence.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

Shutterstock posts record 2025 revenue on AI data growth, but a steep Q4 loss and merger costs reveal deep challenges in its core content business.

eToro reports a record $868M in 2025 net contribution and adds $100M to its buyback, betting on AI and its super-app vision despite a Q4 crypto lull.

Ascend Elements' award to TDK Ventures reveals a new VC model, where hands-on partnership is key to building a secure, circular battery supply chain.

As Xtract One readies its Q2 results, investors eye its booming backlog against a backdrop of rising competition and ethical questions in AI security.

Digital engineering firm Simform invests $3M to scale its Microsoft AI practice, aiming to capture market share with proprietary IP and a co-sell strategy.

Tech giant Sony secures access to crucial 5G, Wi-Fi, and video patents, renewing a long-standing agreement with R&D powerhouse InterDigital.

Now debt-free with $14M in cash, Castellum is leveraging major Navy contracts to fuel its next phase of expansion through acquisitions and innovation.

Fortrea splits key roles, dedicating its CMO to scientific strategy and hiring a new president for clinical pharmacology in a bold post-spin-off move.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

How did a Tennessee 3PL achieve 18x shipment growth? A deep dive into the unified tech platform and AI strategy that’s rewriting the rules of freight.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

A new managed service uses AI to fight advanced cyber threats, offering unified protection and addressing Canadian data sovereignty for North American firms.

Landmark Phase 3 trial results show psilocybin offers rapid, lasting relief for severe depression, pushing psychedelic medicine closer to the mainstream.